Perrigo Company plc $PRGO Shares Sold by O Keefe Stevens Advisory Inc.

O Keefe Stevens Advisory Inc. lowered its stake in shares of Perrigo Company plc (NYSE:PRGO) by 25.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 167,803 shares of the company’s stock after selling 56,600 shares during the quarter. Perrigo comprises about 0.6% of O Keefe Stevens Advisory Inc.’s holdings, making the stock its 24th largest position. O Keefe Stevens Advisory Inc.’s holdings in Perrigo were worth $2,336,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Wealth Enhancement Advisory Services LLC grew its stake in shares of Perrigo by 75.8% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 20,334 shares of the company’s stock valued at $300,000 after purchasing an additional 8,765 shares during the last quarter. GAMMA Investing LLC increased its holdings in shares of Perrigo by 112.6% in the fourth quarter. GAMMA Investing LLC now owns 6,194 shares of the company’s stock valued at $86,000 after purchasing an additional 3,281 shares during the period. Danske Bank A S purchased a new stake in shares of Perrigo during the third quarter worth approximately $53,000. Sherbrooke Park Advisers LLC acquired a new stake in shares of Perrigo during the third quarter worth $286,000. Finally, Lombard Odier Asset Management USA Corp lifted its holdings in shares of Perrigo by 25.7% during the third quarter. Lombard Odier Asset Management USA Corp now owns 98,106 shares of the company’s stock worth $2,185,000 after purchasing an additional 20,040 shares during the period. Institutional investors and hedge funds own 95.91% of the company’s stock.

Perrigo Trading Down 4.2%

NYSE:PRGO opened at $9.25 on Monday. Perrigo Company plc has a 1 year low of $9.23 and a 1 year high of $28.43. The company has a debt-to-equity ratio of 1.23, a quick ratio of 1.63 and a current ratio of 2.76. The stock has a fifty day moving average price of $13.29 and a two-hundred day moving average price of $16.01. The stock has a market capitalization of $1.27 billion, a price-to-earnings ratio of -0.90, a PEG ratio of 1.09 and a beta of 0.41.

Perrigo (NYSE:PRGO) last issued its earnings results on Thursday, February 26th. The company reported $0.77 EPS for the quarter, missing the consensus estimate of $0.80 by ($0.03). Perrigo had a positive return on equity of 9.41% and a negative net margin of 33.51%.The company had revenue of $1.11 billion for the quarter, compared to analysts’ expectations of $1.09 billion. During the same quarter in the previous year, the firm posted $0.93 earnings per share. Perrigo’s revenue for the quarter was down 2.5% on a year-over-year basis. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. As a group, sell-side analysts anticipate that Perrigo Company plc will post 2.56 earnings per share for the current fiscal year.

Perrigo Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 24th. Investors of record on Monday, March 2nd will be issued a dividend of $0.29 per share. The ex-dividend date of this dividend is Monday, March 2nd. This represents a $1.16 dividend on an annualized basis and a yield of 12.5%. Perrigo’s payout ratio is currently -11.28%.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the stock. Weiss Ratings reissued a “sell (d+)” rating on shares of Perrigo in a research note on Monday, December 22nd. Zacks Research upgraded shares of Perrigo from a “strong sell” rating to a “hold” rating in a research note on Friday, February 13th. JPMorgan Chase & Co. lowered their target price on shares of Perrigo from $20.00 to $18.00 and set a “neutral” rating on the stock in a report on Monday, December 15th. Canaccord Genuity Group dropped their price target on shares of Perrigo from $20.00 to $17.00 and set a “buy” rating on the stock in a research note on Friday, February 27th. Finally, Argus upgraded shares of Perrigo to a “hold” rating in a research report on Wednesday, January 14th. One equities research analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $19.33.

Perrigo News Roundup

Here are the key news stories impacting Perrigo this week:

• Negative Sentiment: Zacks slashed Q1–Q4 2026 and several 2027 quarterly estimates, lowering FY2026 EPS to $2.18 (from $3.00) and FY2027 to $2.53 (from $3.18) — signaling weaker near‑term profit expectations and prompting a “Hold” stance. MarketBeat: Zacks Lowers Perrigo Estimates
• Negative Sentiment: Zacks specifically cut quarterly EPS forecasts across multiple quarters (e.g., Q1 2026 to $0.57 from $0.78; Q2 2026 to $0.45 from $0.63; Q3/Q4 2026 and several 2027 quarters also reduced), increasing the risk that Perrigo will need to re‑accelerate margins or growth to meet consensus. MarketBeat: Zacks Lowers Quarterly Estimates
• Negative Sentiment: Separate coverage summarizing Zacks’ Q2 estimate and commentary reiterated the weaker consensus outlook for near‑term EPS — reinforcing the market’s negative reaction to the downgraded profitability trajectory. Zacks Research Estimates Perrigo’s Q2 Earnings

Perrigo Profile

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.